Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
VRCA - Verrica Pharmaceuticals Inc.
Market Cap 225.16M P/E - EPS this Y 1.40% Ern Qtrly Grth -
Income -67M Forward P/E -4.76 EPS next Y 41.80% 50D Avg Chg -11.00%
Sales 5.12M PEG 0.06 EPS past 5Y - 200D Avg Chg 4.00%
Dividend N/A Price/Book 3.47 EPS next 5Y -78.20% 52W High Chg -38.00%
Recommedations 1.80 Quick Ratio 4.35 Shares Outstanding 42.42M 52W Low Chg 166.00%
Insider Own 39.70% ROA -62.56% Shares Float 15.08M Beta 1.91
Inst Own 42.57% ROE -224.08% Shares Shorted/Prior 3.84M/4.40M Price 5.38
Gross Margin -260.29% Profit Margin - Avg. Volume 370,083 Target Price 13.00
Oper. Margin -1,036.17% Earnings Date May 7 Volume 256,755 Change -4.10%
Healthcare | Biotechnology | United States
About Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

Verrica Pharmaceuticals Inc. News
04/25/24 Strength Seen in Amneal (AMRX): Can Its 12.0% Jump Turn into More Strength?
04/03/24 Strong week for Verrica Pharmaceuticals (NASDAQ:VRCA) shareholders doesn't alleviate pain of three-year loss
04/02/24 Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
03/26/24 Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA
03/02/24 When Will Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Become Profitable?
03/02/24 Verrica Pharmaceuticals Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Line
03/01/24 Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q4 2023 Earnings Call Transcript
02/29/24 Verrica Pharmaceuticals Inc (VRCA) Reports Fourth Quarter and Full-Year 2023 Financial Results
02/29/24 Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results
07:30 AM Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference
02/22/24 Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024
02/05/24 Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition
01/29/24 Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH™ from Centers for Medicare and Medicaid Services
01/22/24 7 Potential Short-Squeeze Stocks Poised for Rapid Gains
01/05/24 Verrica Pharmaceuticals Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma
01/04/24 Verrica Pharmaceuticals Announces Receipt of Minutes from Type C Meeting with FDA Regarding Clinical Development of YCANTH™ for the Treatment of Common Warts
01/03/24 Verrica Pharmaceuticals Announces Specialty Pharmacy Partnership Agreement with Walgreens to Distribute YCANTH™
12/24/23 Despite recent sales, Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) insiders remain the largest stockholders with 39% ownership
12/15/23 Verrica Pharmaceuticals’ Development and Commercialization Partner, Torii Pharmaceutical Co., Ltd., Announces Positive Top-line Results from a Confirmatory Phase 3 Trial of TO-208 for the Treatment of Molluscum Contagiosum in Japan
11/11/23 Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q3 2023 Earnings Call Transcript
VRCA Chatroom

User Image GI197845 Posted - 3 days ago

$VRCA What's the proxy vote for? A reverse split? Or, a drastic and severe dilution? Or, a shelf offering? Or more stock options and inducements???

User Image Thestocktraderhubzee Posted - 2 weeks ago

$VRCA Needham Reiterates Buy on Verrica Pharmaceuticals, Maintains $8 Price Target

User Image yogi888 Posted - 2 weeks ago

$VRCA this is the progressionthat should have happened after fda approval. the pipekine is deep and the managenent is well positioned for sucess

User Image Motohead125 Posted - 2 weeks ago

$VRCA Any ideas on why the recent strength here? Is there any data release imminent?

User Image Phase3 Posted - 3 weeks ago

$VRCA Almost gave up on this a while back...

User Image Kittinvestments Posted - 3 weeks ago

$VRCA currently $280M valuation. Should probably be twice to thrice that…

User Image Sebastien3 Posted - 3 weeks ago

$VRCA I love this stock

User Image Motohead125 Posted - 3 weeks ago

$VRCA good little recovery run. Needs about $1 for me to be happy for the interim.

User Image Stock_Titan Posted - 3 weeks ago

$VRCA Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference https://www.stocktitan.net/news/VRCA/verrica-pharmaceuticals-announces-presentation-at-the-23rd-annual-7xdxw8yq32uz.html

User Image Phase3 Posted - 03/28/24

$VRCA

User Image Sebastien3 Posted - 03/28/24

$VRCA Nice and steady here

User Image GI197845 Posted - 1 month ago

$VRCA I'm glad VRCA is up today. I guess it must be due to this article and increased volume? Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA

User Image Kittinvestments Posted - 1 month ago

$VRCA this is good!!! NCE for ycanth is really good. Time to push common warts and make billions!!$$$

User Image momeymaker1 Posted - 1 month ago

$VRCA ooooof

User Image TA_Kongen Posted - 1 month ago

$VRCA Not gonna bite.

User Image momeymaker1 Posted - 1 month ago

$VRCA light volume in small

User Image Stock_Titan Posted - 1 month ago

$VRCA Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA https://www.stocktitan.net/news/VRCA/verrica-pharmaceuticals-announces-that-ycanth-receives-new-chemical-lwi7m9k5he84.html

User Image GI197845 Posted - 1 month ago

$VRCA My average PPS is 5.19 and down it goes.

User Image GI197845 Posted - 1 month ago

$VRCA From 4.97 to 5.09. I just need it to go to 5.19 to break even, too bad it's not all straight upward.

User Image bankswapsmarket Posted - 1 month ago

$VRCA that is one big ass consolidation bull flag looks like move north coming soon been waiting patiently

User Image GI197845 Posted - 1 month ago

$VRCA Prior to HPV vaccines, genital warts caused by HPV affected roughly 340,000 to 360,000 people annually. About 1 in 100 sexually active adults in the U.S. has genital warts at any given time. Therefore, approximately 340,000 - 360,000 people in the USA have genital warts.

User Image GI197845 Posted - 1 month ago

$VRCA The very next catalyst for better or worse is the Q1 2024 earning results will be announced between May 7-13th 2024. Unfortunately, a (final) loss in 2025 is expected, followed by a break even sometime around March 2026, before generating positive profits of $14million at the end of 2026.

User Image GI197845 Posted - 1 month ago

$VRCA Well, a next, big, upcoming catalyst, is that the PIII trial results VP-102 to treat genital and common warts will be announced.

User Image yogi888 Posted - 1 month ago

$VRCA p ipeline is key . the company will be sold at around thirty five . probably ayear frim now

User Image Motohead125 Posted - 1 month ago

$VRCA this has been disappointing

User Image Kittinvestments Posted - 1 month ago

$VRCA the CeO did mention that they will get $10M +$8M payments from their Japanese partner once they start phase 3 for common warts and file regulatory approval for Ycanth in Japan. So we should expect all of that to happen this year (near the end of the year).

User Image Leodus Posted - 1 month ago

$VRCA somebody sitting in the bear trap here

User Image GI197845 Posted - 1 month ago

$VRCA I hope Verrica Pharmaceuticals Inc can cure all sorts of skin warts and such, with FDA approval.

User Image Kittinvestments Posted - 1 month ago

$VRCA I hope they put some good news soon. The stock price is not reflective of the revenue potential…

User Image ValeHold Posted - 1 month ago

$VRCA

Analyst Ratings
Needham Buy Apr 10, 24
Needham Buy Mar 1, 24
HC Wainwright & Co. Buy Mar 1, 24
Jefferies Buy Dec 15, 23
Needham Buy Nov 10, 23
HC Wainwright & Co. Buy Oct 12, 23
Needham Buy Aug 23, 23
Needham Buy Aug 10, 23
HC Wainwright & Co. Buy Jul 27, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
PERCEPTIVE ADVISORS LLC 10% Owner 10% Owner Dec 27 Buy 7.17 321,616 2,305,987 7,099,182 12/29/23
PERCEPTIVE ADVISORS LLC 10% Owner 10% Owner Dec 21 Buy 6.44 504,652 3,249,959 6,777,566 12/26/23
PERCEPTIVE ADVISORS LLC 10% Owner 10% Owner Dec 15 Buy 5.58 1,233,931 6,885,335 6,272,914 12/19/23
Manning Paul B Director Director Jul 24 Buy 5.02 200,000 1,004,000 7,851,128 07/24/23
Hayes Christopher G. Chief Legal Officer Chief Legal Officer Jul 11 Buy 3.40 7,500 25,500 15,714 07/11/22
PERCEPTIVE ADVISORS LLC 10% Owner 10% Owner Jul 05 Buy 2.10 1,428,571 2,999,999 5,038,983 07/05/22